The standard of care for stage 1 (I) NSCLC is removal of the tumor by surgery. However, surgery requires a patient to stay in the hospital for the procedure and recovery. Stereotactic radiotherapy, an alternative treatment for stage 1 (I) NSCLC involving very precise radiation delivery to a tumor, is being used more and more. Stereotactic radiotherapy is an outpatient procedure, meaning patients can avoid staying in the hospital. Although stereotactic radiotherapy can be beneficial to patients and their recovery, doctors do not know for sure if it is as effective at treating the tumor as surgery. This makes deciding when to use stereotactic radiotherapy instead of surgery difficult for stage 1 (I) NSCLC patients and their doctors.

GO2 for Lung Cancer staff directly engaged with the VALOR study team while the study was being designed; to provide input from lung cancer survivors and we continue to be a proud supporter of the trial. The study was led by Dr. Drew Moghanaki, MD, who is a member of our Global Advisory Council, as well as Dr. Tomer Karas, MD.